Cerebrospinal fluid response to structured treatment interruption after virological failure

AIDS

Volumn 15, Issue 10, 2001, Pages 1251-1259

  Price, R W ^a   Paxinos, E E ^a   Grant, R M ^a   Drews, B ^a   Nilsson, A ^a   Hoh, R ^a   Hellmann, N S ^a   Petropoulos, C J ^a   Deeks, S G ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

AIDS; Antiretroviral treatment; Central nervous system; Cerebrospinal fluid; Genotypic resistance; HIV; Phenotypic resistance; Structured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MALE; PHENOTYPE; PLEOCYTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RNA, VIRAL; VIRAL LOAD;

EID: 0035816358     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107060-00006     Document Type: Article

References (28)

1. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
2. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
3. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/ml
4. Antiretroviral resistance during successful therapy of HIV type 1 infection
5. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
6. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
7. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
8. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
9. Control of HIV despite the discontinuation of antiretroviral therapy
10. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
11. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
12. Structured treatment interruptions to control HIV-1 infection
13. Structured treatment interruption in chronically HIV-1 infected patients after longterm viral suppression
14. Virologic and imunnologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia
15. Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: Window into brain infection?
16. Time course of cerebrospinal fluid (CSF) responses to antiretroviral therapy: Evidence for variable compartmentalization of infection
17. A novel phenotypic drug suseptibility assay for human immunodeficiency virus type 1
18. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values
19. The AIDS dementia complex
20. Neurological outcomes in oate HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy
21. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome
22. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources
23. Lymphocyte entry and the initiation of inflammation in the central nervous system
24. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
25. Flow cytometric analysis of cerebrospinal fluid (CSF) T-lymphocytes in HIV infection: Feasibility and initial cross-sectional and longitudinal observations
26. The two faces of cerebrospinal fluid (CSF) HIV infection
27. Acute meningoencephalitis on dose reduction of zidovudine
28. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome